D. Boral Capital Reaffirms Buy Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $5.00 price target on the stock.

Separately, StockNews.com started coverage on VolitionRx in a report on Friday. They issued a “sell” rating on the stock.

VolitionRx Stock Up 4.2 %

VNRX opened at $0.55 on Monday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.02. The business has a 50 day moving average price of $0.59 and a two-hundred day moving average price of $0.64. The company has a market cap of $50.97 million, a PE ratio of -1.53 and a beta of 1.09.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds acquired 181,818 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, with a total value of $99,999.90. Following the purchase, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Several large investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in shares of VolitionRx in the 4th quarter worth about $36,000. Lagoda Investment Management L.P. grew its holdings in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. Northern Trust Corp increased its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of VolitionRx during the fourth quarter valued at $29,000. Finally, Geode Capital Management LLC increased its position in VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.